Nitric oxide pathway as new drug targets for refractory hypertension

Current Pharmaceutical Design

Volumn 11, Issue 25, 2005, Pages 3307-3315

  Augustyniak, Robert A ^a   Thomas, Gail D ^a   Victor, Ronald G ^a   Zhang, Weiguo ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; ARGININE; ASCORBIC ACID; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTROGEN; FIBROBLAST GROWTH FACTOR; GLYCERYL TRINITRATE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOSOME; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE DONOR; PLACEBO; SILDENAFIL; SUPEROXIDE DISMUTASE; TEMPOL;

ADD ON THERAPY; ANTIHYPERTENSIVE ACTIVITY; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EXERCISE; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; HYPERTENSION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; VIRAL GENE THERAPY;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ARGININE; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OMEGA-N-METHYLARGININE; SIGNAL TRANSDUCTION; SUPEROXIDES;

EID: 24944506507     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161205774424672     Document Type: Review

References (88)

1. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-12.
2. Bredt DS, Snyder SH. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 1990; 87: 682-5.
3. Cho HJ, Xie QW, Calaycay J, Mumford RA, Swiderek KM, Lee TD, et al.. Calmodulin is a subunit of nitric oxide synthase from macrophages. J Exp Med 1992; 176: 599-604.
4. Xie QW, Cho HJ, Calaycay J, Mumford RA, Swiderek KM, Lee TD, et al.. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science 1992; 256: 225-8.
5. Buttery LD, Springall DR, Chester AH, Evans TJ, Standfield EN, Parums DV, et al.. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest 1996; 75: 77-85.
6. Lamas S, Marsden PA, Li GK, Tempst P, Michel T. Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform. Proc Natl Acad Sci USA 1992; 89: 6348-52.
7. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
8. Shaul PW. Regulation of endothelial nitric oxide synthase: location, location, location. Annu Rev Physiol 2002; 64: 749-74.
9. Couet J, Li S, Okamoto T, Scherer PE, Lisanti MP. Molecular and cellular biology of caveolae: paradoxes and plasticities. Trends Cardiovasc Med 1997; 7: 103-110.
10. Bredt DS, Hwang PM, Glatt CE, Lowenstein C, Reed RR, Snyder SH. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature 1991; 351: 714-8.
11. Garthwaite J, Charles SL, Chess-Williams R. Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature 1988; 336: 385-8.
12. Schuman EM, Madison DV. Nitric oxide and synaptic function. Annu Rev Neurosci 1994; 17: 153-83.
13. Samdani AF, Dawson TM, Dawson VL. Nitric oxide synthase in models of focal ischemia. Stroke 1997; 28: 1283-8.
14. Sander M, Hansen PG, Victor RG. Sympathetically mediated hypertension caused by chronic inhibition of nitric oxide. Hypertension 1995; 26: 691-5.
15. Sander M, Hansen J, Victor RG. The sympathetic nervous system is involved in the maintenance but not initiation of the hypertension induced by N(omega)-nitro-L-arginine methyl ester. Hypertension 1997; 30: 64-70.
16. Zanzinger J. Role of nitric oxide in the neural control of cardiovascular function. Cardiovasc Res 1999; 43: 639-49.
17. Thomas GD, Zhang W, Victor RG. Nitric oxide deficiency as a cause of clinical hypertension: promising new drug targets for refractory hypertension. JAMA 2001; 285: 2055-7.
18. Traystman RJ, Moore LE, Helfaer MA, Davis S, Banasiak K, Williams M, et al.. Nitro-L-arginine analogues. Dose- and time-related nitric oxide synthase inhibition in brain. Stroke 1995; 26: 864-9.
19. Hansen J, Jacobsen TN, Victor RG. Is nitric oxide involved in the tonic inhibition of central sympathetic outflow in humans? Hypertension 1994; 24: 439-44.
20. Sander M, Chavoshan B, Victor RG. A large blood pressure-raising effect of nitric oxide synthase inhibition in humans. Hypertension 1999; 33: 937-42.
21. Kutcher, Lohman. Der Nachweis toxischer Basen im Harn. Ztschr f physiol Chem 1908; 49: 81.
22. Major RH. Relationship between certain products of metabolism and arterial hypertension. JAMA 1924; 83: 81-84.
23. Leiper J, Valiance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999; 43: 542-8.
24. Calver A, Collier J, Leone A, Moncada S, Vallance P. Effect of local intra-arterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J Hum Hypertens 1993; 7: 193-4.
25. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, et al.. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003; 23: 1455-9.
26. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, Frolich JC, et al.. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004; 109: 172-7.
27. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-5.
28. Kielstein JT, Bode-Boger SM, Frolich JC, Haller H, Boger RH. Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease. Kidney Int Suppl 2001; 78: S9-13.
29. Kielstein JT, Boger RH, Bode-Boger SM, Schaffer J, Barbey M, Koch KM, et al.. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999; 10: 594-600.
30. Schmidt RJ, Domico J, Samsell LS, Yokota S, Tracy TS, Sorkin MI, et al.. Indices of activity of the nitric oxide system in hemodialysis patients. Am J Kidney Dis 1999; 34: 228-34.
31. Xiao S, Wagner L, Schmidt RJ, Baylis C. Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease. Kidney Int 2001; 59: 1466-72.
32. Fleck C, Janz A, Schweitzer F, Karge E, Schwertfeger M, Stein G. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients. Kidney Int Suppl 2001; 78: S14-8.
33. Xiao S, Schmidt RJ, Baylis C. Plasma from ESRD patients inhibits nitric oxide synthase activity in cultured human and bovine endothelial cells. Acta Physiol Scand 2000; 168: 175-9.
34. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS, et al.. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 1999; 343 Pt 1: 209-14.
35. Birdsey GM, Leiper JM, Vallance P. Intracellular localization of dimethylarginine dimethylaminohydrolase overexpressed in an endothelial cell line. Acta Physiol Scand 2000; 168: 73-9.
36. Tojo A, Welch WJ, Bremer V, Kimoto M, Kimura K, Omata M, et al.. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int 1997; 52: 1593-601.
37. MacAllister RJ, Parry H, Kimoto M, Ogawa T, Russell RJ, Hodson H, et al.. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996; 119: 1533-40.
38. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99: 3092-5.
39. Matsuoka H, Itoh S, Kimoto M, Kohno K, Tamai O, Wada Y, et al.. Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension 1997; 29: 242-7.
40. Chen PY, Sanders PW. L-arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest 1991; 88: 1559-67.
41. Zhang W, Pettersson A, Thoren P, Hedner T. Effects of 1, 1-dimethylguanidine administration on blood pressure, heart rate and renal sympathetic nerve activity in normotensive and spontaneously hypertensive rats. Acta Physiol Scand 1997; 159: 1-6.
42. Yamada SS, Sassaki AL, Fujihara CK, Malheiros DM, De Nucci G, Zatz R. Effect of salt intake and inhibitor dose on arterial hypertension and renal injury induced by chronic nitric oxide blockade. Hypertension 1996; 27: 1165-72.
43. Fujiwara N, Osanai T, Kamada T, Katoh T, Takahashi K, Okumura K. Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: modulation of nitric oxide synthesis by salt intake. Circulation 2000; 101: 856-61.
44. Bragulat E, de la Sierra A, Antonio MT, Coca A. Endothelial dysfunction in salt-sensitive essential hypertension. Hypertension 2001; 37: 444-8.
45. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, et al.. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995; 377: 239-42.
46. Kojda G, Laursen JB, Ramasamy S, Kent JD, Kurz S, Burchfield J, et al.. Protein expression, vascular reactivity and soluble guanylate cyclase activity in mice lacking the endothelial cell nitric oxide synthase: contributions of NOS isoforms to blood pressure and heart rate control. Cardiovasc Res 1999; 42: 206-13.
47. Shesely EG, Maeda N, Kim HS, Desai KM, Krege JH, Laubach VE, et al.. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1996; 93: 13176-81.
48. Huang Z, Huang PL, Panahian N, Dalkara T, Fishman MC, Moskowitz MA. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science 1994; 265: 1883-5.
49. Node K, Kitakaze M, Yoshikawa H, Kosaka H, Hori M. Reduced plasma concentrations of nitrogen oxide in individuals with essential hypertension. Hypertension 1997; 30: 405-8.
50. Schmidt RJ, Baylis C. Total nitric oxide production is low in patients with chronic renal disease. Kidney Int 2000; 58: 1261-6.
51. Vaziri ND, Ni Z, Wang XQ, Oveisi F, Zhou XJ. Downregulation of nitric oxide synthase in chronic renal insufficiency: role of excess PTH. Am J Physiol 1998; 274: F642-9.
52. Jachymova M, Horky K, Bultas J, Kozich V, Jindra A, Peleska J, et al.. Association of the Glu298Asp polymorphism in the endothelial nitric oxide synthase gene with essential hypertension resistant to conventional therapy. Biochem Biophys Res Commun 2001; 284: 426-30.
53. Hyndman ME, Parsons HG, Verma S, Bridge PJ, Edworthy S, Jones C, et al.. The T-786-->C mutation in endothelial nitric oxide synthase is associated with hypertension. Hypertension 2002; 39: 919-22.
54. Miyamoto Y, Saito Y, Kajiyama N, Yoshimura M, Shimasaki Y, Nakayama M, et al.. Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension 1998; 32: 3-8.
55. Kato N, Sugiyama T, Morita H, Nabika T, Kurihara H, Yamori Y, et al.. Lack of evidence for association between the endothelial nitric oxide synthase gene and hypertension. Hypertension 1999; 33: 933-6.
56. Benjafield AV, Morris BJ. Association analyses of endothelial nitric oxide synthase gene polymorphisms in essential hypertension. Am J Hypertens 2000; 13: 994-8.
57. Tsujita Y, Baba S, Yamauchi R, Mannami T, Kinoshita M, Yamamoto R, et al.. Association analyses between genetic polymorphisms of endothelial nitric oxide synthase gene and hypertension in Japanese: The Suita Study. J Hypertens 2001; 19: 1941-8.
58. von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, et al.. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995; 92: 1137-41.
59. Lake-Bruse KD, Faraci FM, Shesely EG, Maeda N, Sigmund CD, Heistad DD. Gene transfer of endothelial nitric oxide synthase (eNOS) in eNOS-deficient mice. Am J Physiol 1999; 277: H770-6.
60. Ohashi Y, Kawashima S, Hirata K, Yamashita T, Ishida T, Inoue N, et al.. Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. J Clin Invest 1998; 102: 2061-71.
61. Lin KF, Chao L, Chao J. Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery. Hypertension 1997; 30: 307-13.
62. Cuevas P, Garcia-Calvo M, Carceller F, Reimers D, Zazo M, Cuevas B, et al.. Correction of hypertension by normalization of endothelial levels of fibroblast growth factor and nitric oxide synthase in spontaneously hypertensive rats. Proc Natl Acad Sci USA 1996; 93: 11996-2001.
63. Balon TW, Nadler JL. Evidence that nitric oxide increases glucose transport in skeletal muscle. J Appl Physiol 1997; 82: 359-63.
64. Laufs U, La Fata V, Plutzk J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-35.
65. Indolfi C, Torella D, Coppola C, Curcio A, Rodriguez F, Bilancio A, et al.. Physical training increases eNOS vascular expression and activity and reduces restenosis after balloon angioplasty or arterial stenting in rats. Circ Res 2002; 91: 1190-7.
66. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al.. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 49-57.
67. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, et al.. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 58-66.
68. Waters DD, Alderman EL, Hsia J, Howard BV, Cobb FR, Rogers WJ, et al.. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002; 288: 2432-40.
69. Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG, Moncada S. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci USA 1994; 91: 5212-6.
70. Cheitlin MD, Hutter AM Jr, Brindis RG, Ganz P, Kaul S, Russell RO Jr, et al.. Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Circulation 1999; 99: 168-77.
71. Thomas GD, Zhang W, Victor RG. Impaired modulation of sympathetic vasoconstriction in contracting skeletal muscle of rats with chronic myocardial infarctions: role of oxidative stress. Circ Res 2001; 88: 816-23.
72. Zhang WM, Wang Z, Zhang W. Characterizing blood pressure, heart rate, physical activity, circadian rhythm and their response to NOS inhibitor and substrate in CHF rats with telemetry. Vasc Dis Prev 2004; 1: 159-166.
73. Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, Karoui H, et al.. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci USA 1998; 95: 9220-5.
74. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, et al.. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003; 111: 1201-9.
75. Hong HJ, Hsiao G, Cheng TH, Yen MH. Supplemention with tetrahydrobiopterin suppresses the development of hypertension in spontaneously hypertensive rats. Hypertension 2001; 38: 1044-8.
76. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501.
77. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 1997; 95: 588-93.
78. Hasdan G, Benchetrit S, Rashid G, Green J, Bernheim J, Rathaus M. Endothelial dysfunction and hypertension in 5/6 nephrectomized rats are mediated by vascular superoxide. Kidney Int 2002; 61: 586-90.
79. Schnackenberg CG, Welch WJ, Wilcox CS. Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: role of nitric oxide. Hypertension 1998; 32: 59-64.
80. Brosnan MJ, Hamilton CA, Graham D, Lygate CA, Jardine E, Dominiczak AF. Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. J Hypertens 2002; 20: 281-6.
81. Duffy SJ, Gokce N, Holbrook M, Huang A, Frei B, Keaney JF, Jr., et al.. Treatment of hypertension with ascorbic acid. Lancet 1999; 354: 2048-9.
82. Ness AR, Chee D, Elliott P. Vitamin C and blood pressure-an overview. J Hum Hypertens 1997; 11: 343-50.
83. Panza JA, Quyyumi AA, Brush JE, Jr., Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-7.
84. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993; 21: 929-33.
85. Taddei S, Virdis A, Mattei P, Ghiadoni L, Sudano I, Salvetti A. Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation 1996; 94: 1298-303.
86. Ganotakis ES, Papadakis JA, Vrentzos GE, Mikhailidis DP. The effects of antihypertensive therapy on haemostatic parameters. Curr Pharm Design 2003; 9(29): 2445-64.
87. Nadar S, Blann AD, Lip GY. Endothelial dysfunction: methods of assessment and application to hypertension. Curr Pharm Design 2004; 10(29): 3591-605.
88. Portaluppi F, Boari B, Manfredini R. Oxidative stress in essential hypertension. Curr Pharm Design 2004; 10(14): 1695-8.